Overview of Sekena

What is Sekena: Definition and Pharmacological Class

Property	Description
Active ingredient	Mesalazine (5-aminosalicylic acid, 5-ASA)
Form	Tablets, Suppositories, Enemas
Pharmacological class	Aminosalicylate, Anti-inflammatory agent
Common purpose	Management of bowel inflammation
Origin	Synthetic compound

Sekena is a prescription-only medication whose active component is Mesalazine, which is the internationally recognized name for the chemical compound 5-aminosalicylic acid (5-ASA). It is classified pharmacologically as an aminosalicylate, belonging to a specific group of synthetic anti-inflammatory agents. Aminosalicylates are recognized as a cornerstone of therapy due to their ability to reduce inflammation. This medicine is utilized for its role in targeting and calming inflammatory processes within the body. The parent compound, 5-aminosalicylic acid, is an aromatic amine that is structurally related to salicylates. Mesalazine is considered a single active ingredient product. This classification is vital because the drug's action is designed to be highly localized, directly targeting the intestinal lining where inflammation occurs, a fundamental characteristic that distinguishes it from systemic anti-inflammatory drugs.

Mesalazine: Composition, Forms, and General Purpose

The composition of Sekena is centered on the active component Mesalazine combined with various pharmaceutical excipients that facilitate targeted delivery. As a key active component in the management of inflammatory bowel disease, Mesalazine is supplied in multiple forms, including various oral tablets (such as delayed- or extended-release formulations) and rectal forms like suppositories and enemas. These different forms represent a core differentiating factor, allowing flexibility in treatment based on the area of inflammation. The drug may be administered via the oral route for release in the lower bowel, or via the rectal route for local action in the distal colon. By concentrating its effect locally and working to suppress the inflammatory process within the digestive tract, the primary general purpose of Mesalazine is to support the long-term management of chronic conditions characterized by sustained bowel inflammation, such as when maintaining remission in patients.

Regulatory References

NIH/NCBI Drug Information

What side effects are possible with Sekena?

Possible Side Effects and Safety Information

The safety profile of Sekena (Mesalazine) is established through official regulatory documentation, classifying potential adverse reactions by frequency and the body system affected.

Common and Expected Adverse Reactions

Adverse reactions classified as common (occurring in 1% to 10% of patients) according to regulatory labeling often involve the Gastrointestinal Disorders and Nervous System Disorders systems. Frequently reported effects include headache, nausea, abdominal pain, diarrhea, and vomiting.

System-Organ Class	Examples of Documented Effects
Gastrointestinal Disorders	Abdominal pain, Nausea, Diarrhea, Acute Pancreatitis
Nervous System Disorders	Headache, Dizziness
Renal and Urinary Disorders	Renal impairment, Nephrolithiasis, Urine discoloration

Serious Adverse Reactions

Official labels highlight several serious adverse reactions, which, while uncommon, are clinically significant. These include Mesalamine-Induced Acute Intolerance Syndrome, which can present with cramping and bloody diarrhea. Serious organ toxicities documented in regulatory sources include Renal Impairment (such as interstitial nephritis) and Hepatic Failure.

Rare but serious Severe Cutaneous Adverse Reactions (SCARs), such as Stevens-Johnson syndrome (SJS) and Toxic Epidermal Necrolysis (TEN), have also been reported. Myocarditis and Pericarditis are further examples of uncommon systemic effects noted in official documentation.

Population-Specific Safety Notes

Regulatory documents advise caution for specific patient groups. Use is generally not recommended or requires particular caution in individuals with severe renal or hepatic impairment. Furthermore, renal function is recommended to be evaluated prior to and periodically during therapy. For older adults, caution is advised due to potential increased susceptibility to adverse effects like blood disorders.

Overdose and Emergency Response

The official regulatory profile for Sekena (Mesalazine) focuses on managing the potential for severe systemic toxicity rather than a distinct massive overdose syndrome. Regulatory labeling often notes that no specific cases of acute massive overdose have been reported in humans. However, due to the drug's classification, potential overdose presentations may include signs of salicylate toxicity, such as nausea, vomiting, abdominal pain, headache, confusion, and ringing in the ears.

When Immediate Medical Help is Required: Immediate medical evaluation is mandated if symptoms of severe, life-threatening outcomes are observed, as these complications are documented in association with high systemic exposure or severe hypersensitivity reactions. These critical manifestations include signs of organ involvement such as myocarditis (heart inflammation), pericarditis, nephritis leading to renal failure, hepatic failure, and severe cutaneous adverse reactions (e.g., Stevens-Johnson syndrome). If the acute intolerance syndrome is suspected—indicated by severe abdominal pain or bloody diarrhea—prompt discontinuation is required.

Official Management and Monitoring: In cases of suspected exposure, the official emergency response is symptomatic and supportive treatment at a hospital. No specific antidote is known or documented in the prescribing information. Management requires close monitoring of renal function, which is critical because patients with impaired liver or kidney functions face a potentially increased risk of toxicity due to decreased drug elimination.

Therapeutic Uses of Sekena

What Sekena Treats: Main Uses and Benefits

Sekena (Mesalazine) is commonly used to help manage symptoms related to inflammatory states and manifestations of chronic bowel conditions. It is an anti-inflammatory agent prescribed to treat conditions that cause swelling and sores in the lining of the colon. The therapeutic role generally involves managing active symptomatic periods and contributing to long-term stability in conditions where symptoms may intensify temporarily.

“Sekena is considered relevant for patients with conditions such as Ulcerative Colitis, Ulcerative Proctitis, and certain forms of Crohn's Disease, supporting the patient during difficult episodes by easing distress.”

Treating Active Disease and Maintaining Stability

This medication addresses symptoms related to inflammatory conditions characterized by periods of heightened symptoms. It is applied to ease challenging symptoms, such as symptoms related to physical discomfort like frequent and urgent bowel movements, abdominal discomfort, and rectal bleeding. Sekena is also commonly used for long-term management to help prevent the cyclical return of symptoms that interfere with daily functioning in patients with established disease. This supportive therapeutic benefit generally assists with maintaining functional stability, and may help patients cope more steadily with symptom fluctuations.

Quick Fact: Relief for Inflammation-Driven Symptoms

Localized and Systemic Management

The medication is relevant for managing inflammation localized to the lower bowel, such as the rectum and sigmoid colon, and is applicable within clinical settings that involve acute or disruptive symptom patterns across the colon. It contributes to improved comfort during symptomatic periods and supports general well-being during these phases.

Regulatory References

NIH MedlinePlus overview

Eligibility and Restrictions for Use

Sekena (Mesalazine) use is defined by specific population eligibility rules established in official regulatory labeling.

Contraindications (Must Not Use)

The medicine is strictly contraindicated for patients with a known hypersensitivity to salicylates, aminosalicylates, or any of the product's components. Use is also prohibited in individuals with severe renal impairment (typically GFR <30 ml/min/1.73 m^2) or severe hepatic impairment, as documented in prescribing information. Reintroduction is contraindicated if a mesalazine-induced allergic cardiac reaction is suspected.

Age-Group and Conditional Eligibility

Sekena is approved for adults and for specific pediatric patients who meet minimum age and weight requirements, such as those aged five years or older and weighing at least 24 kg. Use is not recommended or contraindicated in infants and very young children. Older adults should use the medicine with caution, typically requiring monitoring of renal function.

Special Restrictions

Patients with pre-existing conditions, including mild to moderate kidney or liver impairment, chronic lung function impairment (like asthma), or an active peptic ulcer, must only use Sekena with caution and often require specific monitoring. During pregnancy and lactation, use is restricted and permitted only when the treating physician determines the therapeutic benefits clearly outweigh the potential risks, as stated in regulatory guidance.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The interaction profile of Sekena (Mesalazine) is defined by documented exposure-altering and pharmacodynamic interactions with other specific drug categories, as stated in regulatory prescribing information. All information focuses strictly on officially documented interaction patterns and restrictions.

Pharmacodynamic and Exposure-Altering Interactions

Co-administration with certain medicinal products requires regulatory caution due to the potential for increased risk of adverse outcomes.

Azathioprine and 6-Mercaptopurine: Concurrent use of Mesalazine with these purine analog antimetabolites may increase the risk for severe blood disorders, including leukopenia and profound bone marrow depression. This is an officially described interaction outcome associated with altered exposure of the active metabolite of these drugs.
Nephrotoxic Agents (including NSAIDs): Combining Mesalazine with other medicines that carry a risk of kidney damage, such as Non-Steroidal Anti-Inflammatory Drugs (NSAIDs), may result in an increased risk of renal reactions due to an additive pharmacodynamic effect.

Procedural Interference

Mesalazine may also cause interference with specific clinical laboratory tests. The drug's main metabolite, N-Ac-5-ASA, is officially stated to interfere with the measurement of urinary normetanephrine, which can lead to spuriously elevated test results when analyzed by liquid chromatography with electrochemical detection.

No mandatory timing separation rules are documented in the official regulatory labels for co-administered substances, and no specific interactions with food, alcohol, or herbal products are formally listed.

Mechanism of Action

Pharmacodynamic Mechanism of Mesalazine

The mechanism of action for Mesalazine is strictly localized and multi-targeted, contingent upon direct physical contact with the intestinal mucosa. The molecule exerts its anti-inflammatory influence through three distinct but coordinated mechanistic domains.

First, Mesalazine functions as an inhibitor of key enzymes in the arachidonic acid cascade, specifically Cyclooxygenase (COX) and 5-Lipoxygenase (5-LOX). This interaction directly reduces the local synthesis of pro-inflammatory mediators, including certain prostaglandins and leukotrienes (e.g., LTB4).

Second, the molecule modulates intracellular signaling by interfering with the activation of the transcription factor Nuclear factor-kappa B (NF-,kappaB) and acting as a partial agonist for the nuclear receptor PPAR-,gamma. These actions influence gene expression, shifting the cellular profile towards a state of reduced inflammatory protein production.

Third, Mesalazine acts as a direct scavenger of Reactive Oxygen Species (ROS) and Free Radicals generated during the inflammatory process. This chemical neutralization mitigates the potential for oxidative damage to mucosal tissue. The combination of these molecular events results in a sustained, localized suppression of the inflammatory cascade within the bowel wall.

Dosage and Administration Information

Administration Overview

Sekena is administered as an injection into the muscle (intramuscularly). The administration is performed by a healthcare professional, typically in the gluteal or deltoid muscle. The process is designed to allow for the gradual release of the medication into the bloodstream over an extended period.

Preparation for Treatment

Before the procedure begins, the healthcare professional ensures the medication has reached the appropriate temperature and that the injection site is prepared. Because the medication is a suspension, the vial is typically shaken vigorously to ensure the liquid is consistent and the active ingredients are evenly distributed.

Injection Sites

There are two primary sites used for the administration of this medication:

Deltoid: The upper arm muscle. This site is often used for specific volume requirements or based on patient preference.
Gluteal: The muscle of the buttocks. This site is commonly selected for its ability to accommodate the medication volume and support consistent absorption.

Healthcare professionals may rotate the injection sites between the left and right sides of the body for subsequent appointments to maintain skin and muscle health.

Maintenance and Routine

Following the initial administration, the medication is scheduled at regular intervals. Maintaining a consistent schedule is a standard part of the treatment process to ensure the levels of the medication in the body remain within the therapeutic range. Healthcare providers track the dates of administration to manage the long-term treatment plan.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Sekena (Mesalazine)

Evidence for Active Ulcerative Colitis

Research examining clinical situations related to active Ulcerative Colitis primarily includes short-term Randomized Controlled Trials (RCTs) and systematic reviews. The studies focused on adult patients with mild to moderate disease severity in contexts involving fluctuating or unstable symptoms. Trials were conducted during periods of increased symptom activity and examined outcomes related to physical discomfort, such as the achievement of remission, frequency of bowel movements, and the recorded status of rectal bleeding.

The studies monitored the responses of observed populations over defined time intervals, typically ranging from 6 to 12 weeks. Research highlights changes measured during the study period, and patterns related to clinical status were reported at the end of the short-term induction phase. The long-term effects extending beyond the initial short-term findings are not yet fully established.

Evidence for Maintaining Remission in Quiescent Ulcerative Colitis

Studies exploring the long-term use of Sekena focus on maintenance therapy for conditions characterized by cycles of stability and flare-ups. This research has examined the time to relapse and the maintenance of quiescent states in study groups once remission has been achieved. The evidence includes long-term RCTs that compared Sekena against placebo, and extensive observational cohort studies.

These studies monitored populations for long periods, often a year or more, tracking outcomes linked to inflammatory or irritative states and measuring the time elapsed before the symptoms returned. Studies report patterns related to the stability of remission observed throughout the study periods. Evidence derived from settings with varying symptom burdens indicates that long-term adherence to therapy was observed to significantly influence outcomes, complicating the interpretation of sustained patterns.

Research Gaps and Remaining Uncertainties

While extensive research has been conducted on Sekena, certain aspects are not fully established. Comparative evidence is lacking for head-to-head comparisons of every different oral formulation available on the market, meaning findings were mixed or inconsistent in specific areas of formulation comparisons.

Additionally, data for certain groups remain insufficient, particularly regarding dedicated RCTs studying outcomes in pediatric populations. Research is ongoing, and findings describe group patterns, not personal outcomes, meaning research provides context but not individual predictions regarding symptom control and long-term stability. The primary research focus is centered on Ulcerative Colitis. The evidence for other forms of inflammatory bowel disease, such as Crohn's Disease, indicates that certainty remains low due to inconsistent findings and small sample sizes.

Key Studies & References NIH/NCBI Drug Information: Mesalamine Dosage and Formulation

Frequently Asked Questions (FAQ)

Common questions about Sekena (FAQ)

Q: How quickly should I expect Sekena to start making a difference in my condition?

A: Clinical studies for active disease typically evaluate the medicine's effects over a period of mathbf6 to mathbf12 weeks. The initial treatment course is often prescribed for a limited time, such as mathbf6 to mathbf8 weeks, before transitioning to a long-term maintenance regimen. Clinical studies evaluate outcomes during this initial phase, but individual response times may vary.

Q: Can I safely take Sekena if I also take a daily multivitamin or herbal supplement?

A: Official regulatory labeling does not formally list any specific interactions with general food, alcohol, or herbal products. Information regarding all concurrent products, including vitamins and supplements, is typically reviewed by a healthcare professional.

Q: How long does Sekena typically stay in your system after you stop taking it?

A: Pharmacokinetic data from regulatory sources indicate that the active ingredient, Mesalazine, has a terminal half-life of approximately mathbf7 to mathbf8.5 hours for certain oral formulations. The half-life refers to the time needed for the amount of medicine in the body to decrease by half.

Q: Is it normal to feel a bit nauseous or dizzy when first starting Sekena?

A: Official labeling lists nausea and dizziness as common adverse reactions, meaning they are reported in 1% to 10% of patients in clinical trials. The occurrence of these effects is consistent with the product's official safety profile.

Q: What are the signs that Sekena is actually improving my condition?

A: The effectiveness in clinical trials is generally assessed by measuring changes in the signs of inflammation. These indicators include the achievement of remission, a reduction in the frequency of bowel movements, and a decrease in the status of rectal bleeding.

Q: What is the difference between Sekena and the placebo used in the clinical trials?

A: Sekena is the mathbfactive medicine containing the ingredient Mesalazine that is being studied for its anti-inflammatory effects. A mathbfplacebo is an inactive substance that is used as a control in clinical trials to help researchers measure the actual effect of Sekena versus no treatment.

Q: Are there any long-term effects of taking Sekena that I should be aware of?

A: The medicine has been examined in long-term studies lasting a year or more for the maintenance of remission. Serious long-term effects noted in official documentation, though uncommon, include reports of mathbfrenal impairment (affecting the kidneys) and mathbfhepatic failure (affecting the liver).

Q: What signs should I look out for that would suggest a more serious reaction to Sekena?

A: Official warnings describe a worsening of symptoms that may be associated with mathbfAcute Intolerance Syndrome, which includes severe cramping, bloody diarrhea, fever, headache, and rash. Other serious reactions can include signs of hypersensitivity or severe skin reactions (SCARs).

Q: Are there any specific foods or drinks (like grapefruit juice or alcohol) that must be avoided while on Sekena?

A: Official regulatory documents do not list specific restrictions or interactions with common foods, grapefruit juice, or alcohol. Decisions about diet and concurrent substance use are typically made after consultation with a healthcare professional.

Q: Can Sekena impact fertility or family planning?

A: Official regulatory information notes that Sekena has been associated with mathbfreversible infertility in some males. This is a risk factor documented in humans that is typically reviewed as part of family planning discussions.

Q: Is there a generic version of Sekena available, or is it only brand-name?

A: The active ingredient in Sekena, Mesalazine, is widely available in a variety of authorized generic products as well as different brand-name formulations. Availability may vary depending on location and formulation.

Q: Does taking Sekena require regular blood tests or monitoring?

A: Official guidance indicates that a person's mathbfrenal function (kidney function) is typically assessed prior to and periodically during therapy. For those taking Mesalazine concurrently with certain other immunosuppressant medicines, complete blood cell counts also require monitoring.

Q: Can Sekena cause a metallic taste or changes in appetite?

A: Official labeling lists a loss of appetite (anorexia) as a common effect for some formulations. However, a metallic taste is not specifically listed among the common, uncommon, or rare adverse reactions in official documentation.

Q: What is the likelihood of experiencing a rare side effect mentioned in the leaflet?

A: Official labeling classifies adverse reactions by frequency. Side effects listed as mathbfCommon occur in 1% to 10% of patients, Uncommon in 0.1% to 1%, and Rare in less than 0.1%. For instance, mathbfAcute Intolerance Syndrome was reported in approximately 3% of patients in controlled trials.

Q: Does Sekena make you more sensitive to the sun?

A: Official product information includes a warning about mathbfphotosensitivity reactions. Regulatory advice often suggests minimizing sun exposure, using protective clothing, and applying broad-spectrum sunscreen when outdoors.

Q: Does Sekena cause weight gain or weight loss?

A: Official documentation lists loss of appetite as a common effect for some formulations. Additionally, mathbfweight gain has been noted in postmarketing reports, although the incidence rate for weight gain is not precisely known.

Q: Are there any known long-term non-serious side effects, such as hair thinning?

A: Official adverse reaction reports include hair loss or thinning of the hair (alopecia) as a less common side effect associated with some formulations of the medicine.

Q: Can Sekena interact with contrast dyes used for imaging (like MRIs or CT scans)?

A: Sekena's main metabolite has been shown to interfere with the measurement of mathbfurinary normetanephrine, a substance measured in certain laboratory tests. This interference can lead to false elevated test results, but official documentation does not specifically refer to contrast dyes themselves.

Q: Can Sekena affect sleep patterns, causing insomnia or excessive drowsiness?

A: Anxiety is listed as a rare side effect for some formulations, which could indirectly affect sleep. However, specific sleep disorders such as insomnia or excessive drowsiness are mathbfnot explicitly listed as common or uncommon adverse reactions in official labeling for the drug class.

How should Sekena be stored and disposed of?

How to Store and Dispose of Sekena (Mesalazine)

Sekena (Mesalazine) must be stored and handled according to specific regulatory conditions to maintain its stability and effectiveness.

Official Storage Requirements

Storage Component	Official Requirement
Temperature	Store at controlled room temperature (20 C to 25 C) with permitted excursions.
Protection	Protect from light and excessive moisture. Keep the container tightly closed.
Prohibitions	Do not freeze and do not refrigerate the product.
Child Safety	Keep out of the sight and reach of children.

Disposal Instructions

Unused or expired Sekena must be disposed of according to local regulatory requirements. The medicine should not be flushed down the toilet or disposed of in household wastewater, and official drug take-back programs are generally recommended for discarding unwanted product. Any portion of the drug prepared for immediate use must be discarded immediately after administration.

Sekena